Q5119 HCPCS code: Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Q5119 is the HCPCS Level II code for injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg. In 2024 Medicare paid an average of $15.83 per service for Q5119 across 1,648,407 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 150 per day on outpatient hospital claims. Medicare volume fell 42% from 2022 to 2024 (2,851,296 to 1,648,407 services). In 2024, about 3,044 clinicians billed Medicare for Q5119 for 6,139 beneficiaries; California, Texas, Florida accounted for 34% of services.

Code details

FieldValue
SectionQ codes — Temporary codes
Coverage codeC — Carrier judgment
Pricing indicator51 — Drug or biological (priced per ASP/average sales price rules)
BETOS categoryO1D — Chemotherapy
Added2020-07-01
Last action effective2020-07-01

Who bills Q5119 (2024)

MeasureValue
Clinicians billing (by place of service)3,044
Medicare beneficiaries6,139
States with claims38
Share of services in top 3 states (California, Texas, Florida)34%

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for Q5119, 2022–2024

YearServicesBeneficiariesAvg. allowedAvg. paid
20222,851,2969,809$46.29$36.98
20232,514,2919,121$27.66$22.02
20241,648,4076,139$19.89$15.83

States with the most Q5119 services (2024)

StateServicesAvg. paid
California209,457$15.88
Texas209,124$15.85
Florida137,819$15.73
Illinois131,205$15.94
Virginia109,120$16.00

NCCI unit limits (MUE)

Claim typeMax units per dayRationale
outpatient hospital claims150Prescribing Information
practitioner claims150Prescribing Information

Medicare policy articles for this code

Covered diagnoses (1,052 ICD-10-CM codes)

The diagnoses most often listed as covered in the policy articles above:

ICD-10-CMDiagnosisArticles listing it
D59.0Drug-induced autoimmune hemolytic anemia4
D59.11Warm autoimmune hemolytic anemia4
D59.12Cold autoimmune hemolytic anemia4
D59.13Mixed type autoimmune hemolytic anemia4
D69.3Immune thrombocytopenic purpura4
D69.41Evans syndrome4
D89.811Chronic graft-versus-host disease4
G35.ARelapsing-remitting multiple sclerosis4
G36.0Neuromyelitis optica [Devic]4
G70.00Myasthenia gravis without (acute) exacerbation4

Showing 10 of 1,052. The full list, non-covered diagnoses and CSV export are in Caduvo.

What changed for Q5119

Frequently asked questions

What is HCPCS code Q5119?

Q5119 is the HCPCS Level II code for injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg. Short descriptor: "Inj ruxience, 10 mg".

How much does Medicare pay for Q5119?

In 2024, the average Medicare payment was $15.83 per service (average allowed $19.89).

Does Medicare cover Q5119?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Which diagnoses support coverage for Q5119?

Medicare policy articles that cite Q5119 list 1,052 covered ICD-10-CM diagnosis codes across 4 articles. The most cited include D59.0 (Drug-induced autoimmune hemolytic anemia), D59.11 (Warm autoimmune hemolytic anemia), D59.12 (Cold autoimmune hemolytic anemia). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.

How many units of Q5119 can be billed per day?

150 on outpatient hospital claims; 150 on practitioner claims (NCCI medically unlikely edits).

Related Q51 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All Q codes · HCPCS lookup